PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
NCT ID: NCT06617481
Last Updated: 2024-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2024-09-20
2027-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
NCT07285057
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
NCT05779943
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
NCT06580015
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
NCT05707182
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
NCT06862856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label Main Arm
Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)
18F-rhPSMA-7.3 (Posluma)
PET Scan using Posluma for detection of early recurrence of prostate cancer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-rhPSMA-7.3 (Posluma)
PET Scan using Posluma for detection of early recurrence of prostate cancer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
Exclusion Criteria
* Patients currently receiving Androgen Deprivation Therapy (ADT).
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Blue Earth Diagnostics
INDUSTRY
AdventHealth
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AdventHealth
Orlando, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Guru Sonpavde, MD, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRBNet # 2067493
Identifier Type: OTHER
Identifier Source: secondary_id
AdventH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.